Drug Shortage Report for TEVA-NABILONE

Last updated on 2021-12-02 History
Report ID 149942
Drug Identification Number 02392925
Brand name TEVA-NABILONE
Common or Proper name NABILONE 0.25MG CAPS
Company Name TEVA CANADA LIMITED
Market Status MARKETED
Active Ingredient(s) NABILONE
Strength(s) 0.25MG
Dosage form(s) CAPSULE
Route of administration ORAL ORAL
Packaging size 50
ATC code A04AD
ATC description ANTIEMETICS AND ANTINAUSEANTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2021-11-24
Estimated end date 2022-04-30
Actual end date 2021-11-30
Shortage status Resolved
Updated date 2021-12-02
Company comments Original April '22 date for release was an error
Health Canada comments
Tier 3 Status No
Contact Address 30 NOVOPHARM COURT
TORONTO, ONTARIO
CANADA M1B 2K9
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v4 2021-12-02 French Compare
v3 2021-12-02 English Compare
v2 2021-11-25 French Compare
v1 2021-11-25 English Compare

Showing 1 to 4 of 4